Posts

Posted on

Kraft Hockeyville Reveals Taber, AB and Tumbler Ridge, BC as Top Two Finalists in 20th Anniversary Year

Kraft Hockeyville Reveals Taber, AB and Tumbler Ridge, BC as Top Two Finalists in 20th Anniversary Year

TORONTO–(BUSINESS WIRE)–
Kraft Heinz, in partnership with the National Hockey League (NHL®) and the National Hockey League Players’ Association (NHLPA), announced the top two finalists competing for the title of Kraft Hockeyville 2026: Taber Community Centre in Taber, Alberta and Tumbler Ridge Community Centre Arena in Tumbler Ridge, British Columbia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260321716785/en/

Kraft Hockeyville Reveals Taber, AB and Tumbler Ridge, BC as Top Two Finalists in 20th Anniversary Year

Kraft Hockeyville Reveals Taber, AB and Tumbler Ridge, BC as Top Two Finalists in 20th Anniversary Year

Canadians are encouraged to visit krafthockeyville.ca to cast their votes to determine the winner of Kraft Hockeyville 2026 between April 3, 2026, at 9:00 a.m. ET and April 4, 2026, at 5:00 p.m. ET. The winner will be announced live on April 4, 2026, during the evening Hockey Night in Canada broadcast.

As part of the top two finalist prize structure, the Kraft Hockeyville 2026 winning community will receive $250,000 for rink upgrades, plus the opportunity to host an NHL® Pre-Season game for their community. The runner-up will receive $100,000 for rink upgrades. Each community, along with the other Provincial and Territorial winners, will also receive $10,000 in brand new hockey equipment to help more children play the game courtesy of NHLPA Goals and Dreams and the NHL/NHLPA Industry Growth Fund. For two decades, Kraft Hockeyville has celebrated the arenas that bring communities together, awarding $5.4 million to 105 communities since 2006.

“We’re honoured to mark this Top Two finalist milestone in Kraft Hockeyville’s 20th anniversary year,” said Kelly Fleming, Chief Marketing Officer, Kraft Heinz Canada. “Canadians shared inspiring stories about how their local rinks foster connection, strength and community. That spirit is reflected in this year’s finalists – Taber, Alberta and Tumbler Ridge, British Columbia – where the arena is at the heart of it all.”

To learn more about the top two finalist communities, head to krafthockeyville.ca.

About Kraft Heinz Canada

Kraft Heinz Canada’s heritage can be traced back over a century to when James Lewis Kraft of Stevensville, Ontario began selling cheese from a horse-drawn wagon in 1903. Heinz Canada was established in 1909 in Leamington, Ontario where its first products were pickles sourced from local growers. Following the 2015 merger between Kraft Foods Group and H.J. Heinz Company, Kraft Heinz Canada became a subsidiary of the newly formed Kraft Heinz Company (NASDAQ: KHC). Now the country’s second largest food and beverage company, iconic Kraft Heinz Canada products like Kraft Peanut Butter, Heinz Ketchup, KD, Philadelphia Cream Cheese, Renées Dressing, Jell-O, Classico, Kool-Aid and Maxwell House are found in over 97 per cent of Canadian households.

Kraft Heinz Canada is driving transformation inspired by Kraft Heinz’s global purpose, Let’s Make Life Delicious, by creating memorable community moments through local initiatives and the impactful program we’re celebrating here, Kraft Hockeyville, while also supporting food banks across Canada through Kraft Heinz Groceries for Good program. Learn more about our journey by visiting kraftheinz.com or following us on LinkedIn.

NHL and the NHL Shield are registered trademarks of the National Hockey League. © 2026 NHL. All Rights Reserved.

NHLPA and the NHLPA logo are registered trademarks of the National Hockey League Players’ Association. © NHLPA. All Rights Reserved.

For more information, or to speak with a representative from Kraft Hockeyville, please contact:

The Kraft Heinz Company, [email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Hockey Retail Sports Restaurant/Bar Supermarket Food/Beverage

MEDIA:

Photo
Photo
Kraft Hockeyville Reveals Taber, AB and Tumbler Ridge, BC as Top Two Finalists in 20th Anniversary Year
Logo
Logo
Posted on

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

DUBLIN–(BUSINESS WIRE)–
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner presentations on clinical updates from prasinezumab for the treatment of Parkinson’s disease and BMS-986446 for the treatment of Alzheimer’s disease at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026) in Copenhagen, Denmark, and online.

Roche Presentations on Prasinezumab for the Potential Treatment of Parkinson’s Disease

Industry Symposium – Pathways to Progress: Exploring Innovations in AD and PD for Future Practice

  • Chair: Malú G. Tansey, Ph.D., Indiana University School of Medicine Stark Neuroscience Institute

  • Date: Tuesday March 17, 2026

This symposium reviewed the evolving understanding of the molecular pathophysiology and disease heterogeneity across Alzheimer’s disease (AD) and Parkinson’s disease (PD). Explored current and emerging treatment pathways, e.g. alpha-synuclein, amyloid-beta and neuroinflammation; including diagnostics, biomarkers and therapeutics. Considered how the advancing understanding of AD and PD informs innovative clinical development approaches and clinical practice.

Oral Presentation – Modeling Parkinson’s Disease Progression to Quantify Long-Term Treatment Effects via the Concept of ‘Time Saved’

  • Presenter: Benjamin Ribba, Roche

  • Date: Thursday March 19, 2026

The comparison of PASADENA open-label extension (OLE) data with PPMI-based model predictions supports potential disease-modifying efficacy with an estimated two years of ‘time saved’ providing an intuitive measure of long-term benefit. The observed PASADENA OLE outcomes consistently deviated from the model-predicted progression, suggesting a sustained treatment effect. On average, participants were approximately two years less advanced in disease severity five years after the start of the trial compared to the virtual comparator.

Oral Presentation – Prasinezumab in Early-Stage Parkinson’s Disease: Additional Data from the PADOVA Study

  • Presenter: Tania Nikolcheva, M.D., Ph.D., Roche

  • Date: Saturday March 21, 2026

Longer term data from the PADOVA OLE study in early-stage PD showed a sustained effect of prasinezumab in slowing Parkinson’s progression on top of effective symptomatic therapies. The totality of the evidence suggests a possible clinical benefit of prasinezumab and informed the initiation of the Phase III PARAISO study.

Poster Presentation – Prasinezumab’s Impact on Neuromelanin- and Iron-Sensitive MRI Biomarkers in Parkinson’s Disease: Findings from the PADOVA Phase IIb Study

Exploratory biomarker analysis of PADOVA suggests that prasinezumab is biologically active. This is supported by imaging biomarkers crucial to PD pathology, showing a slowing in the progressive loss of neuromelanin signal in substania nigra pars compacta and reduced iron accumulation in the putamen.

Poster Presentation– Sustained Effect on Prasinezumab on Parkinson’s Disease Motor Progression in the Open-Label Extension of the PASADENA Trial, 5-Year Update

At Year 5, the combined PASADENA arm (delayed- and early-start groups) showed less disease progression compared to the PPMI cohort. This lower progression was observed across multiple measures.

Poster Presentation– Digital Health Technology Detects Group Differences in Practically-Defined OFF L-DOPA State: Results of PADOVA Phase IIb Study of Prasinezumab

Post-hoc Digital Health Technology analyses showed consistent trends favoring prasinezumab in digital data collected in the practically-defined OFF L-DOPA state, in line with the PASADENA Phase 2a Simple Sum digital finding and clinical PADOVA readout.

Bristol Myers Squibb Presentation on BMS-986446 for the Potential Treatment of Alzheimer’s Disease

Oral Presentation– Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BMS-986446 in Healthy Participants, Including Those of Japanese Ethnicity

  • Presenter: Ilena George, M.D., Bristol Myers Squibb

  • Date: Saturday March 21, 2026

Single-dose BMS-986446 was safe and well tolerated in all participants, including those of Japanese ethnicity. Plasma exposure of BMS-986446 increased dose proportionally. No anti-drug antibodies were detected. These results support BMS-986446 dosing in ongoing clinical studies without adjustments for Japanese ethnicity.

About Prasinezumab

Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease.

About Parkinson’s Disease

Parkinson’s disease is a chronic, progressive and debilitating neurodegenerative disease characterized by the gradual loss of neurons that make dopamine and other nerve cells. Today, Parkinson’s disease affects over 10 million people worldwide. The prevalence of Parkinson’s disease is increasing, and it has become one of the fastest-growing neurological disorders. Currently, symptomatic treatments that effectively alleviate motor symptoms are available. However, no therapies slow down or stop the clinical progression of Parkinson’s disease.

About BMS-986446

BMS-986446 is a humanized monoclonal antibody that targets multiple domains of the microtubule binding region of tau, a highly pathogenic tau fragment associated with neurofibrillary tangle formation and cognitive decline in Alzheimer’s disease. BMS-986446 binds to specific regions of the tau protein (R1–R3 within the microtubule-binding domain) to stop cell-to-cell spread of tau and tau uptake into cells. It also activates microglia—the brain’s immune cells—through its Fc receptor function, promoting the clearance of tau via phagocytosis.

About Alzheimer’s Disease

Alzheimer’s disease is a progressive, multifaceted and devastating neurodegenerative disease and the most common type of dementia in adults. Changes in the brain disrupt communication between neurons, impacting memory, cognition and behavior. As a result, Alzheimer’s disease has a significant impact on the day-to-day lives of those it directly affects, as well as on their families, caregivers and friends, resulting in considerable shifts in interpersonal relationships. There remains a critical need for disease-modifying therapies that can slow or delay the progression of Alzheimer’s disease as well as therapies that manage and ease neurobehavioral symptoms.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying CYTOPE®, a noveltechnology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific macromolecular effectors. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to, among other things, the treatment potential, designs, proposed mechanisms of action, and potential administration of prasinezumab and BMS-986446; and the continued advancement of our preclinical and clinical pipeline, including the potential and advancement of CYTOPE. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, as well as those described in the “Risk Factors” sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2026, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.

Mark Johnson, CFA

Senior Vice President, Head of Investor Relations and Corporate Communications

650-837-8550

[email protected]

[email protected]

KEYWORDS: Denmark North America Asia Pacific Japan Europe United States Ireland United Kingdom

INDUSTRY KEYWORDS: Oncology Health Neurology Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

HII Celebrates 2025 Graduates of The Newport News Shipbuilding Apprentice School

NEWPORT NEWS, Va., March 21, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) hosted commencement exercises today, celebrating 128 graduates of the company’s Newport News Shipbuilding Apprentice School. The ceremony was held at Liberty Live Church in Hampton.

Linda McMahon, U.S. secretary of education, delivered the keynote commencement address.

“On the eve of America’s 250th anniversary, I am reminded of how much we have relied on skilled workers to build and sustain our nation,” McMahon told graduates. “Today, you join that proud tradition. This path you have chosen is one of purpose, opportunity, and lasting impact, and it will help carry our country forward for generations to come.”

HII hosted McMahon at NNS Friday for a tour of the shipyard and The Apprentice School. McMahon also participated in a roundtable discussion with shipbuilders focused on workforce development and national security.

At graduation Saturday, NNS President Kari Wilkinson addressed the graduates as the shipyard’s newest leaders.

Photos accompanying this release are available at: http://hii.com/news/hii-celebrates-2025-graduates-of-the-newport-news-shipbuilding-apprentice-school/.

“What an incredible accomplishment this day represents, and it is one deserving of the highest praise and celebration,” Wilkinson said. “Thank you for your commitment and your dedication and for being on this team of professionals doing the work of the nation.”

Founded in 1919, The Newport News Shipbuilding Apprentice School has been accredited since 1982 by the Council on Occupational Education. Certification to grant associate degrees and confer degrees on its own came in July 2020, after the school was approved by the State Council of Higher Education for Virginia to operate as a postsecondary institution.

Alex Edwards received the Homer L. Ferguson Award, which recognizes the apprentice graduating with the highest average in combined required academic and craft grades.

Edwards began his career with HII in 2018 as an electrician at NNS. He entered The Apprentice School in 2022 to further his education and expand his career options. He currently works as a deck electrician on aircraft carrier USS John C. Stennis (CVN 74), which is undergoing refueling and complex overhaul at NNS.

During his address, Edwards acknowledged the support the class has received from family and friends and asked graduates to reflect on their achievements, while focusing on accomplishing their next goals.

“Each of us now has a degree that is a reminder to us that we can accomplish a goal that we commit ourselves to,” Edwards said. “My question to each of you is: What is the next goal you are going to commit to? I believe that each of us can achieve the goals we set if we commit 100 percent of ourselves to them.”

Replay coverage of the ceremony is available at: https://hii.com/events/apprentice-school-graduation/.

The following is a profile of the graduating class:

  • Thirteen graduates earned highest honors, a combination of academic and craft grades that determine overall performance. Thirty-two earned high honors and 13 earned honors.
  • One hundred and five graduates earned an Associate of Applied Science in maritime technology degree.
  • Sixty-nine graduates completed Frontline FAST, an accelerated skills training program for potential foremen.
  • Thirty graduates were inducted into The National Society of Leadership Success.
  • Six graduates are military veterans or are currently serving in the armed services as reservists and guardsmen.
  • Twenty-four graduates earned Gold Athletic awards.

The Apprentice School accepts more than 200 apprentices per year. The school offers four- to eight-year, tuition-free apprenticeships in 19 trades and six optional programs. Apprentices work a 40-hour week and are paid for all work, including time spent in academic classes.

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 44,000 strong. For more information, visit:

Contact:
Todd Corillo
[email protected]
(757) 688-3220

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cb71c7d-2a2e-4496-b28e-86e2489de525



Posted on

INVESTOR ALERT: monday.com Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

SAN DIEGO, March 21, 2026 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that the monday.com class action lawsuit – captioned Potter v. monday.com Ltd., No. 26-cv-01956 (S.D.N.Y.) – seeks to represent purchasers or acquirers of monday.com Ltd. (NASDAQ: MNDY) common stock and charges monday.com as well as certain of monday.com’s top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

monday.com

class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-monday-com-ltd-class-action-lawsuit-mndy.html

You can also contact attorney

J.C. Sanchez

of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

. Lead plaintiff motions for the

monday.com

class action lawsuit must be filed with the court no later than May 11, 2026.

CASE ALLEGATIONS: monday.com, together with its subsidiaries, develops software applications.

The monday.com class action lawsuit alleges that defendants throughout the class period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to monday.com’s projected revenue outlook and anticipated growth on the back of its continued expansion of its core platform, AI-driven investments, increasing enterprise adoption and multi-product integration; (ii) monday.com was seeing new customer growth decelerating, weaker expansion within existing accounts and longer enterprise sales cycles, making monday.com’s $1.8 billion 2027 target increasingly unlikely to be met; and (iii) defendants misled investors by providing the public with materially flawed statements of confidence and growth projections which did not account for these variables.

The monday.com class action lawsuit further alleges that on February 9, 2026, monday.com disclosed that “we will no longer be discussing our previously provided 2027 targets, but we’ll be centering our discussion on our 2026 outlook, which reflects the continued momentum we see across our AI work platform, new product introductions and upmarket sales motion.” On this news, the price of monday.com stock fell nearly 21%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired monday.com common stock during the class period to seek appointment as lead plaintiff in the monday.com class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the monday.com investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the monday.com shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the monday.com class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]



Posted on

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

SEATTLE–(BUSINESS WIRE)–
Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm – 4pm CET in Madrid, Spain. The session, titled “Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,” will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôpital Saint-Antoine, AP-HP, and will feature speakers Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, and Michelle L. Schoettler, MD, MS, Children’s Healthcare of Atlanta.

The EBMT Annual Meeting is a key event for professionals in transplantation and cellular therapy, bringing together stakeholders from around the world.

About Omeros Corporation

Omeros is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros’ lead lectin pathway inhibitor YARTEMLEA® (narsoplimab-wuug), which inhibits the pathway’s effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients aged two years and older. A marketing authorization application for YARTEMLEA in TA-TMA is currently under review at the European Medicines Agency. OMS1029, Omeros’ long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials.

Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), a MASP-3 inhibitor in clinical development for PNH and other alternative pathway indications, along with associated intellectual property and related assets. Omeros’ pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder that is fully funded by the National Institute on Drug Abuse, as well as a growing portfolio of novel molecular and cellular oncology programs. For more information about Omeros and its programs, visit www.omeros.com.

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

[email protected]

KEYWORDS: Washington Europe Spain United States North America

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Logo
Logo
Posted on

INVESTOR ALERT: Gartner, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that the Gartner class action lawsuit – captioned Schmidt v. Gartner, Inc., No. 26-cv-00394 (D. Conn.) – seeks to represent purchasers or acquirers of Gartner, Inc. (NYSE: IT) common stock and charges Gartner and certain of Gartner’s executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

Gartner

class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-gartner-inc-class-action-lawsuit-it.html

You can also contact attorney

J.C. Sanchez

of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

. Lead plaintiff motions for the

Gartner

class action lawsuit must be filed with the court no later than May 18, 2026.

CASE ALLEGATIONS: Gartner provides business and technology insights for decisions and performance on an organization’s mission-critical priorities.

The Gartner class action lawsuit alleges that defendants throughout the class period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Gartner’s contract value (“CV”) growth potential and projected Consulting segment revenue outlook while also minimizing risk from seasonality and macroeconomic fluctuations; (ii) defendants highlighted that the environment among “tariff impacted companies” was “starting to improve,” generating “more certainty” in the demographics, which allegedly would result in the opportunity for continued CV growth for Gartner; and (iii) while tariff impacts continued to ease and settle and companies were acting with more certainty, Gartner’s non-federal CV growth would fall even further as its Consulting segment revenue faltered below Gartner’s long-held projections.

The Gartner class action lawsuit further alleges that on August 5, 2025, Gartner announced its second quarter fiscal 2025 earnings, revealing that its overall CV growth declined from 7% the previous quarter to only 5%; and, the ex-federal CV growth declined from 8% the previous quarter to merely 6%. On this news, the price of Gartner stock fell more than 27%, according to the complaint.

Then, on February 3, 2026, the Gartner class action lawsuit alleges that Gartner announced a significant decline in its CV growth rate, which had faltered another 2% including and excluding federal contracts, and for the first time disclosed a significant shortfall of its Consulting segment’s performance against Gartner’s internal projections. On this news, the price of Gartner stock fell nearly 21%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Gartner common stock during the class period to seek appointment as lead plaintiff in the Gartner class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Gartner investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Gartner shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Gartner class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]



Posted on

Fortinet Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortinet Inc. – FTNT

Fortinet Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortinet Inc. – FTNT

NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fortinet Inc. (the “Company”) (NasdaqGS: FTNT).

On August 6, 2025, the Company disclosed disappointing second-quarter 2025 financial results, including that it was already “approximately 40% to 50% of the way through the 2026 upgrade cycle at the end of the second quarter [of 2025] based on the remaining active units and service contracts,” that excess [firewall] capacity by customers meant less demand for upgrades, and also issued weaker-than-expected revenue guidance for the upcoming third quarter, projecting revenue between $1.67 billion and $1.73 billion.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing.

KSF’s investigation is focusing on whether Fortinet’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Fortinet shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-ftnt/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

1-877-515-1850

KEYWORDS: United States North America Louisiana New York

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

Gartner, Inc. Securities Fraud Class Action Result of Reduced Guidance Disclosure and 48% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Gartner, Inc. Securities Fraud Class Action Result of Reduced Guidance Disclosure and 48% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have untilMay 18, 2026 to file lead plaintiff applications in a securities class action lawsuit against Gartner, Inc. (NYSE: IT) (“Gartner” or the “Company”), if they purchased or otherwise acquired the Company’s shares between February 4, 2025, and February 2, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Connecticut.

What You May Do

If you purchased shares of Gartner and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-it/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 18, 2026.

About the Lawsuit

Gartner and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 5, 2025, the Company announced its 2Q 2025 results, disclosing that overall contract value (“CV”) growth declined from 7% the previous quarter to only 5%, and ex-federal CV growth declined from 8% the previous quarter to only 6%. On this news, the price of Gartner’s shares fell from a closing price of $336.71 per share on August 4, 2025, to $243.93 per share on August 5, 2025, a decline of about 27.55% in the span of just a single day.

Then, on February 3, 2026, the Company disclosed that its CV growth rate had continued to decline another 2% both including and excluding federal contracts, and for the first time disclosed a significant shortfall of its Consulting segment’s performance against the Company’s internal projections. On this news, the price of Gartner’s shares fell from a closing price of $202.40 per share on February 2, 2026, to $160.16 per share on February 3, 2026, a decline of nearly 20.87% in the span of one day.

The case is Schmidt v. Gartner, Inc., No. 26-cv-00394.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

1-877-515-1850

1100 Poydras St., Suite 960

New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

KEYWORDS: United States North America Connecticut New York Louisiana

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

Oxbridge Re Announces 2025 Fourth Quarter Results on March 30, 2026

GRAND CAYMAN, Cayman Islands, March 20, 2026 (GLOBE NEWSWIRE) — Oxbridge Re Holdings Limited (NASDAQ: OXBR), (the “Company”), which together with its subsidiaries is engaged in the business of tokenized Real-World Assets (“RWAs”), initially in the form of tokenized reinsurance securities, and reinsurance business solutions to property and casualty today, announced that it plans to hold a conference call on Monday March 30, 2026 at 4:30 p.m. Eastern time to discuss results for the fourth quarter and year ending December 31, 2025. Financial results will be issued in a press release after the close of the market on the same day. Oxbridge Re’s management will host the conference call, followed by a question and answer period.

Interested parties can listen to the live presentation by dialing the listen-only number below.

Date: March 30, 2026
Time: 4:30 p.m. Eastern time
Listen-only toll-free number: 877 524-8416
Listen-only international number: +1 412 902-1028
 

Please call the conference telephone number 10 minutes before the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact InComm Conferencing at +1-201-493-6280

A replay of the call will be available by telephone after 4:30 p.m. Eastern time on the same day of the call until April 13, 2026.

Toll-free replay number: 877-660-6853
International replay number: +1 201-612-7415
Replay passcode: 13759252
 

About Oxbridge Re Holdings Limited


Oxbridge Re Holdings Limited
 (NASDAQ: OXBR, OXBRW) (“Oxbridge Re”) is headquartered in the Cayman Islands. The company offers tokenized Real-World Assets (“RWAs”) as tokenized reinsurance securities and reinsurance business solutions to property and casualty insurers, through its subsidiaries SurancePlus Inc, Oxbridge Re NS, and Oxbridge Reinsurance Limited.

Insurance businesses in the Gulf Coast region of the United States purchase property and casualty reinsurance through our licensed reinsurers Oxbridge Reinsurance Limited and Oxbridge Re NS.

Our Web3-focused subsidiary, SurancePlus Inc., has developed the first “on-chain” reinsurance RWA of its kind to be sponsored by a subsidiary of a publicly traded company. By digitizing interests in reinsurance contracts as on-chain RWAs, SurancePlus has democratized the availability of reinsurance as an alternative investment to both U.S. and non-U.S. investors.

Company Contact:
Oxbridge Re Holdings Limited
Jay Madhu, CEO
+1 345-749-7570
[email protected]



Posted on

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, March 20, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that it has closed an initial tranche (“First Tranche”) of the offering announced on March 10, 2026 and March 11, 2026 (collectively, the “Announcement NRs”) and has issued 3,750 Debenture Units (as defined in the Announcement NRs) for $3,750,000.

The Company will use the proceeds from the First Tranche for the ongoing development of the Company’s business model and for general working capital purposes.

One director of the Company (the “Director Subscriber”) participated in the Offering (as defined in the Announcement NRs) and subscribed for Debenture Units representing aggregate gross proceeds of $300,000. The participation by the Director Subscriber in the Offering constitutes a “related party transaction” as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction exceeds 25% of the Company’s market capitalization, as determined in accordance with MI 61-101. The Company did not file a material change report in respect of the related party aspects of the Director Subscriber’s participation in the Offering at least 21 days before the closing of the Offering, which the Company deems reasonable in the circumstances in order to expedite the completion of the Offering.

Debt Settlement

In addition, the Company has completed an initial batch of the Debt Settlement (as defined in the Announcement NRs) by issuing an aggregate of 370,457 Class B subordinate voting shares in the Company (each, a “Class B Share”) to settle approximately $1,117,727 of debt owed to certain arm’s length creditors and insiders of the Company.

The participation by insiders of the Company in the Debt Settlement constitutes a “related party transaction” as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction exceeds 25% of the Company’s market capitalization, as determined in accordance with MI 61-101. The Company did not file a material change report in respect of the related party aspects of the Debt Settlement at least 21 days before the closing of the Debt Settlement, which the Company deems reasonable in the circumstances in order to expedite the completion of the Debt Settlement.

All amounts in this press release are expressed in Canadian dollars.

The securities described herein have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, Quantum BioPharma retains a large tax loss carry forward of approximately C$130 million and could be utilized in the future to offset tax payable obligations against future profits. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses.

Forward-Looking Information

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements relating to: the closing of the Offering and the Debt Settlement; the use of proceeds from the Offering; and the Shares issued pursuant to the Debt Settlement, and potential issuance of Shares and Debenture Units.

Forward-looking information in this press release is based on certain assumptions and expected future events, including but not limited to: the Company has the ability to complete additional tranches of the Offering and the Debt Settlement.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: risks relating to the Company’s business and operations generally; and the reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Contacts:

Quantum BioPharma Ltd.

Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: [email protected]
Telephone: (416) 854-8884

Investor Relations
Email: [email protected], [email protected]
Website: www.quantumbiopharma.com